CJC-1295 + Ipamorelin Blend 5/5mg – 10 Vial Box

Description

Description

CJC-1295 (without DAC) is a synthetic GHRH analogue investigated for its interactions with pituitary somatotroph GHRH receptor signaling and its observed effects on endogenous GH secretion dynamics and IGF-1 expression regulation. Ipamorelin is a selective growth hormone secretagogue studied for its interactions with ghrelin receptor (GHSR-1a) signaling and its observed effects on GH pulse amplitude modulation via a mechanism distinct from GHRH receptor activation.

These compounds are investigated in combination for their complementary and mechanistically distinct receptor pathway interactions, with research examining their combined effects on somatotropic axis signaling dynamics.

For Research Use Only. Not for Human Consumption.

Minimum order quantity: one box (10 vials x 5/5 mg, 50 mg of each in total).

Note: Product images show branded labels for illustration purposes only. All peptides are shipped in wholesale, unbranded packaging. You can see an actual example photo of the peptide vials and container above.

Specifications

Additional information

Research

1. Raun, Kirsten, et al. "Ipamorelin, the first selective growth hormone secretagogue." European journal of endocrinology 139.5 (1998): 552-561.
2. Andersen, N. B., et al. "The growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation of adult rats." Growth Hormone & IGF Research 11.5 (2001): 266-272.
3. Beck, David E., et al. "Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients." International journal of colorectal disease 29 (2014): 1527-1534.
4. Gobburu, Jogarao VS, et al. "Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers." Pharmaceutical research 16 (1999): 1412-1416.
5. Schally, Andrew V., et al. "Actions and potential therapeutic applications of growth hormone–releasing hormone agonists." Endocrinology 160.7 (2019): 1600-1612.
6. Valcavi, R., et al. "Growth hormone responses to GRF 1–29 in patients with primary hypothyroidism before and during replacement therapy with thyroxine." Clinical endocrinology 24.6 (1986): 693-698.
7. Ionescu, Madalina, and Lawrence A. Frohman. "Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog." The Journal of Clinical Endocrinology & Metabolism 91.12 (2006): 4792-4797.
8. Teichman, Sam L., et al. "Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults." The Journal of Clinical Endocrinology & Metabolism 91.3 (2006): 799-805.

Testing Docs